RBP4 as a novel adipokine, it has also been associated with obesity-related co-morbidities including insulin resistance, dyslipidemia, type 2 diabetes and coronary heart disease [19, 20, 33, 34], while these obesity-related diseases are well-established risk factor for breast cancer. Here, RBP4 is linked to obesity disorder.